Product Images Doxorubicin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Doxorubicin Hydrochloride NDC 0069-4031 by Pfizer Laboratories Div Pfizer Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - doxorubicin 01

Chemical Structure - doxorubicin 01

Figure 1 - doxorubicin 02

Figure 1 - doxorubicin 02

This text appears to contain information about hazard ratios from various trials comparing different treatments, such as Doxo-based treatments in comparison to CMF. It seems to include data from NSABP B-15, SECSG 2, ONCOFRANCE, SE Sweden, BCGA, NSABC Israel, BR0283, Austrian BCSG 3, and other studies. Additionally, it mentions the boundary of non-inferiority with CMF at a specific ratio.*

Figure 2 - doxorubicin 03

Figure 2 - doxorubicin 03

Logo - doxorubicin 04

Logo - doxorubicin 04

Logo - doxorubicin 04a

Logo - doxorubicin 04a

PRINCIPAL DISPLAY PANEL - 10 mg/5 mL ONCO-TAIN® Label - doxorubicin 05

PRINCIPAL DISPLAY PANEL - 10 mg/5 mL ONCO-TAIN® Label - doxorubicin 05

This text contains information about a hazardous drug called DOXOrubicin Hydrochloride Injection, which is a single-dose vial prescription for intravenous use only. It is recommended to discard any unused portion, store refrigerated between 2°C and 8°C (36°F and 46°F), and protect from light. The recommended dosage is 10 mg/5 mL (2 mg/ml). The label mentions the manufacturer as Qilu Pharmaceutical Co., Ltd in New York, NY.*

PRINCIPAL DISPLAY PANEL - 10 mg/5 mL ONCO-TAIN® Carton - doxorubicin 06

PRINCIPAL DISPLAY PANEL - 10 mg/5 mL ONCO-TAIN® Carton - doxorubicin 06

This text is a detailed label for a medication called DOXOrubicin Hydrochloride Injection. It includes important information such as dosage, storage instructions, warning about being a hazardous drug, and pharmaceutical details. The medication is intended for intravenous use only and should be stored refrigerated and protected from light. Each milliliter contains 2 mg of DOXOrubicin hydrochloride and 9 mg of sodium chloride. It is recommended to refer to the prescribing information for the correct dosage and usage instructions.*

PRINCIPAL DISPLAY PANEL - 20 mg/10 mL ONCO-TAIN® Label - doxorubicin 07

PRINCIPAL DISPLAY PANEL - 20 mg/10 mL ONCO-TAIN® Label - doxorubicin 07

This is a description of a medication labeled NDC 0069-4031-12, which is likely an oncologic solution called DOXOrubicin Hydrochloride Injection. It advises to store the medication refrigerated between 2°C and 8°C and for intravenous use only. It recommends referring to the prescribing information for dosage instructions. The product is distributed by Pfizer Labs and contains 20 mg/10 mL (2 mg/ml). The text also mentions a warning about the hazardous nature of the drug.*

PRINCIPAL DISPLAY PANEL - 20 mg/10 mL ONCO-TAIN® Carton - doxorubicin 08

PRINCIPAL DISPLAY PANEL - 20 mg/10 mL ONCO-TAIN® Carton - doxorubicin 08

This is a drug label for a medication called "IDOXOrubicin Hydrochloride Injection" with a concentration of 20 mg/10 mL. It is intended for intravenous use only and should be stored refrigerated between 2°C and 8°C (36°F and 46°F). The solution contains 2 mg of doxorubicin hydrochloride (equivalent to 1.917 mg of doxorubicin) and 9 mg of sodium chloride per milliliter, with a pH adjusted to 3.0. The text mentions discarding unused portions and includes dosage instructions. The medication is distributed by Pfizer under the brand Novaplus.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.